ESCAPE Bio is a clinical-stage biopharmaceutical company focused on the discovery and development of precision small molecule therapies to treat genetically defined subpopulations in neurodegenerative diseases. We believe that developing therapies precisely targeted towards a perturbed pathway or genetic variant will ultimately address the root cause of disease, thereby potentially improving probability of success compared to less-selective approaches or those that target downstream manifestations of disease.

Executive Management

Julie Anne Smith
President & Chief Executive Officer
Mark Kaufmann
Chief Financial Officer &
Chief Business Officer
Teresa McWhirt
SVP- Head of Human Relations
Carrolee Barlow, MD, PhD
Chief Medical Officer
Paul Wren, PhD
Chief Scientific Officer

Board of Directors

Laura Brass, PhD
Senior Investment Partner, Novartis Venture Fund
Perry Karsen
Gladstone Institutes
Peter Moldt, PhD
Partner, Novo Ventures
Scott Morrison
Independent Director
Edward Owens
Independent Director
Julie Anne Smith
President & Chief Executive Officer
Peter Thompson, MD
Private Equity Partner,
R. Sanders (Sandy) Williams, MD
Independent Director
Asish K. Xavier, PhD
Vice President, Venture Investments Johnson
& Johnson Innovation – JJDC, Inc.


4000 Shoreline Court, Suite 400 South San Francisco, CA 94080 650-431-0100